Shares of Moderna dropped 2.18% to $140.87 at 11:55 EST on Friday, following yesterday’s upward trend. The Nasdaq Stock Market is falling 0.26% to $12,731.30, after four consecutive sessions in a row of gains. This seems, so far, a somewhat rough trend exchanging session today.

Moderna’s last close was $144.00, 26.71% under its 52-week high of $178.50.

News about Moderna today

Moderna shot expected to bolster U.S. vaccine efforts. According to today’s article on The Wall Street Journal, "The U.S. Food and Drug Administration may issue an emergency authorization for a vaccine from Moderna Inc. as early as Friday after an advisory panel recommended the agency approve its use. ", "Moderna expects to add 20 million doses of its vaccine to Pfizer’s expected U.S. supply of 25 million in December."

Moderna authorization bid to get quick FDA attention, hahn says. According to today’s article on Bloomberg Quint, "The U.S. Food and Drug Administration will work quickly toward authorizing Moderna Inc.’s Covid-19 vaccine that agency advisers voted Thursday to recommend, Commissioner Stephen Hahn said.", "The regulator told Moderna "that it will rapidly work toward finalization and issuance of an emergency use authorization," Hahn said late Thursday in a statement. "

FDA speeds toward Moderna vaccine authorization as soon as today. According to today’s article on Bloomberg Quint, "Anthony Fauci, the top U.S. infectious disease expert, said on NBC’s "Today" show that he expected Moderna’s vaccine would begin to be administered "by the very early part of next week. ", "Moderna’s vaccine is expected to play an important role in the government’s plans for mass immunization and slowing the pandemic. "

Moderna’s Sales

Moderna’s sales growth is 1665.3% for the current quarter and 15587.1% for the next. The company’s growth estimates for the current quarter is a negative 32.4% and positive 685.7% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $140.87 at 11:55 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s value is way higher than its 50-day moving average of $112.48 and way higher than its 200-day moving average of $79.47.

Previous days news about Moderna

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to The Wall Street Journal on Tue Dec 15, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to Bloomberg Quint on Tue Dec 15, "Once the U.S. grants authorization, advisers to the Centers for Disease Control and Prevention must meet, as they did last week on Pfizer’s vaccine, to give Moderna’s shot the green light and provide offer specific recommendations for use and monitoring. ", "Moderna’s vaccine isn’t yet approved in any other countries and hasn’t yet been used on anyone outside of a clinical trial."

Moderna vaccine found safe, effective before key FDA review. According to Bloomberg Quint on Tue Dec 15, "In addition, there were two cases of serious facial swelling in vaccine recipients that Moderna determined were related to vaccination. ", "The FDA got a much deeper look at Moderna’s clinical-trial data than the numbers previously released to the public by the company. "

Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to MarketWatch on Tue Dec 15, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company’s COVID-19 vaccine candidate is “highly effective” at preventing infections with the coronavirus. "

Canada to receive early access to Moderna Covid-19 vaccine. According to Business Insider on Tue Dec 15, "Moderna submitted an application for regulatory review of its COVID-19 vaccine candidate under Health Canada’s interim order on October 12, 2020. ", "Today, the Honourable Anita Anand, Minister of Public Services and Procurement, announced that following successful negotiations and contingent on Health Canada authorization of the vaccine, Canada will be able to access 168,000 doses of the Moderna COVID-19 vaccine in December 2020."

Moderna to offer covid shots to volunteers who got placebo. According to Bloomberg Quint on Tue Dec 15, "Moderna Inc. is preparing to offer its Covid-19 shot to trial participants who received a placebo in the final-stage study once the vaccine is authorized for emergency use in the U.S.", "Ray Jordan, a Moderna spokesman, confirmed the letter was being prepared."

Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Moderna (MRNA) – Moderna was downgraded to "hold" from "buy" at Jefferies, which cited the significant runup in the drugmaker’s stock as well as high expectations surrounding its Covid-19 vaccine. "

Moderna party ending, analysts caution before shot approval. According to Bloomberg Quint on Wed Dec 16, "As one of the top biotech outperformers for the year, Moderna is also a prime target for bears. ", "Moderna Inc’s swift rise — much of it driven by daytraders speculating over the chances of its Covid-19 vaccine getting approval — is picking up more detractors on Wall Street by the day."

FDA panel expected to back Moderna Covid-19 vaccine. According to The Wall Street Journal on Thu Dec 17, "A federal vaccine-advisory committee is likely to recommend that the Food and Drug Administration grant an emergency-use authorization for the new Covid-19 vaccine from Moderna Inc. when the panel meets Thursday, its chairman said."

Global market outlook for the coronavirus vaccine market to 2027, featuring Moderna inc, geovax, inovio pharmaceuticals and more. According to Business Insider on Thu Dec 17, "Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.", "Key Topics Covered:1 Executive Summary 2 Preface3 Market Trend Analysis4 Porters Five Force Analysis5 Global Coronavirus Vaccine Market, By Infection Type6 Global Coronavirus Vaccine Market, By Vaccine Type7 Global Coronavirus Vaccine Market, By Product Type8 Global Coronavirus Vaccine Market, By Route of Administration9 Global Coronavirus Vaccine Market, By Patient Type10 Global Coronavirus Vaccine Market, By End User11 Global Coronavirus Vaccine Market, By Geography12 Key Developments13 Company Profiling13.1 Inovio Pharmaceuticals, Inc. 13.2 Moderna, Inc. 13.3 Protein Potential, LLC 13.4 Novavax, Inc. 13.5 Synairgen PLC 13.6 AlphaVax, Inc. 13.7 NanoViricides, Inc. 13.8 Zydus Cadila 13.9 Bravovax 13.10 GeoVax 13.11 Altimmune 13.12 Janssen Pharmaceutical Companies 13.13 CanSino Biologics 13.14 Vaxart 13.15 Vaxil Bio Ltd For more information about this report visit https://www.researchandmarkets.com/r/5b6t0s"

FDA advisory panel endorses use of Moderna Covid-19 vaccine. According to MarketWatch on Thu Dec 17, "An independent advisory committee on Thursday voted 20-0-1 that the benefits of Moderna Inc.’s COVID-19 vaccine candidate outweigh the risks, a recommendation that sets the stage for the likely second FDA authorization of a vaccine during the pandemic.", "Shares of Moderna gained 1.2% in after-hours trading on Thursday after the vote."

Moderna ditches 400,000 vaccine doses but still set to meet goal. According to Bloomberg Quint on Thu Dec 17, "The 400,000-dose loss, meanwhile, is somewhat of a drop in the bucket for Moderna’s overarching objective of producing 500 million to 1 billion doses in 2021. ", "Moderna’s two-dose regimen employs messenger RNA technology similar to that used in the Pfizer Inc.-BioNTech SE vaccine authorized for emergency use by the Food and Drug Administration last week. "

Experts back Moderna vaccine; n.y. toll above 100: virus update. According to Bloomberg Quint on Thu Dec 17, "Moderna’s product is based on the same technology as a shot made by Pfizer Inc. and BioNTech SE that was cleared by the FDA last week, and like that vaccine showed a high degree of efficacy in late-stage clinical trials. ", "The Evergreen State, which has about 7.6 million residents, would also get 183,800 doses of Moderna’s vaccine this month if that inoculation is approved by regulators. "

LEAVE A REPLY

Please enter your comment!
Please enter your name here